Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Pharmacological characterization of the opioid inactive isomers (+)‐naltrexone and (+)‐naloxone as antagonists of toll‐like receptor 4

Open access
Wang, X, Zhang, Y, Peng, Y, Hutchinson, M R, Rice, K C, Yin, H, Watkins, L R · 2016 · British Journal of Pharmacology

Abstract

Background and Purpose: The toll‐like receptor TLR4 is involved in neuropathic pain and in drug reward and reinforcement. The opioid inactive isomers (+)‐naltrexone and (+)‐naloxone act as TLR4 antagonists, reversing neuropathic pain and reducing opioid and cocaine reward and reinforcement. However, how these agents modulate TLR4 signalling is not clear. Here, we have elucidated the molecular mechanism of (+)‐naltrexone and (+)‐naloxone on TLR4 signalling. Experimental Approach: BV‐2 mouse microglial cell line, primary rat microglia and primary rat peritoneal macrophages were treated with LPS and TLR4 signalling inhibitors. Effects were measured using Western blotting, luciferase reporter assays, fluorescence microscopy and ELISA Key Results: (+)‐Naltrexone and (+)‐naloxone were equi‐potent inhibitors of the LPS‐induced TLR4 downstream signalling and induction of the pro‐inflammatory factors NO and TNF‐α. Similarly, (+)‐naltrexone or (+)‐naloxone inhibited production of reactive oxygen species and increased microglial phagocytosis, induced by LPS. However, (+)‐naltrexone and (+)‐naloxone did not directly inhibit the increased production of IL‐1β, induced by LPS. The drug interaction of (+)‐naloxone and (+)‐naltrexone was additive. (+)‐Naltrexone or (+)‐naloxone inhibited LPS‐induced activation of IFN regulatory factor 3 and production of IFN‐β. However, they did not inhibit TLR4 signalling via the activation of either NF‐κB, p38 or JNK in these cellular models. Conclusions and Implications: (+)‐Naltrexone and (+)‐naloxone were TRIF‐IFN regulatory factor 3 axis‐biased TLR4 antagonists. They blocked TLR4 downstream signalling leading to NO, TNF‐α and reactive oxygen species. This pattern may explain, at least in part, the in vivo therapeutic effects of (+)‐naltrexone and (+)‐naloxone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13394

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Wang, X., Zhang, Y., Peng, Y., Hutchinson, M. R., Rice, K. C., Yin, H., & Watkins, L. R.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2016-02-04
Volume
173
Issue
5
Pages
856-869
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2412243856
Cited by
173
References
9
FWCI
5.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.